Antimicrobial resistance (AMR) occurs when pathogens evolve to evade the drugs designed to kill them, representing one of the greatest threats to global health. Bacterial AMR directly caused 1.27 million deaths in 2019 and is projected to cause up to 39 million deaths globally between 2025 and 2050. It severely jeopardizes modern medical procedures, making routine surgeries, organ transplants, and cancer chemotherapy increasingly dangerous due to the risk of untreatable opportunistic infections.

Molecular Mechanisms of Resistance Bacteria employ several sophisticated defense strategies to neutralize or expel antibiotics:

• Enzymatic Degradation: Bacteria produce enzymes like β-lactamases that break down the antibiotic's molecular structure, rendering it ineffective.
• Efflux Pumps: Membrane transport proteins (such as the RND, MFS, and ABC superfamilies) actively pump drugs out of the bacterial cell, lowering the internal antibiotic concentration to sub-lethal levels.
• Target Modification: Bacteria genetically alter the specific cellular sites that antibiotics target, preventing the drug from binding effectively.
• Reduced Permeability & Biofilms: Bacteria can alter their outer membranes (e.g., losing porin channels) to block drugs, or form thick, protective biofilms that shield them from both antibiotics and the host's immune system.

These resistance traits rapidly spread among bacterial populations through horizontal gene transfer (HGT) via mobile genetic elements like plasmids and transposons.

2024 WHO Bacterial Priority Pathogens List (BPPL) To guide global research, the WHO categorizes antibiotic-resistant bacteria into priority tiers. The "Critical" priority tier highlights pathogens causing severe, untreatable infections, particularly in hospital settings. This includes carbapenem-resistant Acinetobacter baumannii, carbapenem- and third-generation cephalosporin-resistant Enterobacterales, and rifampicin-resistant Mycobacterium tuberculosis. The "High" priority tier includes severe community-acquired threats like fluoroquinolone-resistant Salmonella and Shigella, and Methicillin-resistant Staphylococcus aureus (MRSA).

Next-Generation Therapeutics and Stewardship With the traditional antibiotic pipeline dwindling, scientists are developing novel biotherapeutics:

• CRISPR-Cas9 Systems: Used to precisely target and cleave specific antibiotic resistance genes within bacteria, thereby re-sensitizing them to existing antibiotics.
• Bacteriophage Therapy: Employs bacterial viruses (phages) to infect and lyse specific resistant bacteria. Phages can penetrate biofilms and evolve alongside pathogens.
• Monoclonal Antibodies (mAbs): Precision immune proteins designed to neutralize bacterial toxins or block pathogen adhesion without disrupting the patient's beneficial microbiome.
• Nanobiotics and Antimicrobial Peptides (AMPs): New delivery platforms and natural compounds (like animal venoms) offer alternative ways to destroy bacterial cell membranes.

Combating AMR also requires rigorous antimicrobial stewardship, such as implementing the WHO AWaRe (Access, Watch, Reserve) framework to optimize antibiotic prescribing, alongside a One Health approach that addresses antibiotic misuse holistically across human medicine, agriculture, and the environment.